拟议地舒单抗生物类似药SB16与参照地舒单抗治疗绝经后骨质疏松症:3期结果至第12个月
这项3期随机、双盲、多中心研究纳入457例绝经后骨质疏松症患者,比较SB16与参照地舒单抗(DEN)的生物相似性。第12个月腰椎骨密度较基线变化百分比的组间最小二乘均值差异在全分析集为0.33%(90%CI -0.25至0.91),在符合方案集为0.39%(95%CI -0.36至1.13),均在预设等效界值内。药代动力学、药效动力学、安全性和免疫原性数据支持SB16与DEN的生物相似性。
要点
- 第12个月腰椎骨密度变化百分比的组间差异在全分析集为0.33%(90%CI -0.25至0.91),在符合方案集为0.39%(95%CI -0.36至1.13),均在预设等效界值内。
- 次要终点包括腰椎(第12个月除外)、全髋和股骨颈骨密度变化百分比以及药代动力学、药效动力学、安全性和免疫原性,两组间具有可比性。
- 研究结论认为报告的有效性、药代动力学、药效动力学、安全性和免疫原性数据支持SB16与DEN的生物相似性。
核心结论
- 报告的有效性、药代动力学、药效动力学、安全性和免疫原性数据支持SB16与参照地舒单抗(DEN)的生物相似性。
研究设计与样本
- 这项3期随机、双盲、多中心研究纳入457例腰椎或全髋T值介于-2.5至-4的绝经后骨质疏松症患者(NCT04664959)。
- 患者按1:1比例随机接受60 mg SB16或DEN皮下注射,于第0个月和第6个月给药;第12个月时重新随机分组,继续原 assigned 治疗或从DEN切换至SB16至第18个月;本报告包含至第12个月的结果。
主要发现
- 第12个月腰椎骨密度较基线变化百分比的组间最小二乘均值差异在全分析集为0.33%(90%CI -0.25至0.91),在符合方案集为0.39%(95%CI -0.36至1.13)。
- 次要终点包括腰椎(第12个月除外)、全髋和股骨颈骨密度变化百分比以及药代动力学、药效动力学(血清I型胶原C端肽和I型前胶原N端前肽)、安全性和免疫原性,两组间具有可比性。
关键数值与推荐
- 第12个月腰椎骨密度变化百分比组间差异在全分析集为0.33%(90%CI -0.25至0.91),在符合方案集为0.39%(95%CI -0.36至1.13),均在预设等效界值内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: SB16 is a proposed biosimilar to reference denosumab (DEN; brand name: Prolia). OBJECTIVE: This phase 3 randomized, double-blind, multicenter study evaluated the biosimilarity of SB16 to DEN in women with postmenopausal osteoporosis (NCT04664959). DESIGN: The study included 457 postmenopausal osteoporosis patients who had a lumbar spine or total hip T-score between -2.5 and -4. Patients were randomized in a 1:1 ratio to receive either 60 mg of SB16 or DEN subcutaneously at month 0 and month 6. At month 12, patients were rerandomized to continue with the assigned treatment or switch from DEN to SB16 up to month 18. This report includes results up to month 12. METHODS: The primary endpoint was the percent change from baseline in lumbar spine bone mineral density (BMD) at month 12. Secondary endpoints including the percent change from baseline in BMD of the lumbar spine (except for month 12), total hip, and femoral neck; pharmacokinetic, pharmacodynamic (serum C-telopeptide of type I collagen, and procollagen type I N-terminal propeptide), safety, and immunogenicity profiles were measured up to month 12. RESULTS: The least-squares mean differences in percent change from baseline in lumbar spine BMD at month 12 were 0.33% (90% CI, -0.25 to 0.91) in the full analysis set and 0.39% (95% CI, -0.36 to 1.13) in the per-protocol set; both within the predefined equivalence margin. The secondary endpoints were comparable between the 2 treatment groups. CONCLUSION: The reported efficacy, pharmacokinetic, pharmacodynamic, safety, and immunogenicity data support the biosimilarity of SB16 to DEN.
引用
- Langdahl B, Chung YS, Plebanski R, et al. Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12. J Clin Endocrinol Metab. 2025. PMID: 39243386. doi:10.1210/clinem/dgae611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。